Background: Current guidelines on chronic spontaneous urticaria (CSU) suggest a
treatment based on a 3-step approach that aims at total symptom control, starting with H1 …

The effectiveness of omalizumab in chronic spontaneous urticaria (CSU) and symptomatic
dermographism has been demonstrated in many clinical and real-life studies. 1, 2 A wide …

Omalizumab is a monoclonal anti-IgE antibody that has been approved to treat
antihistamine-refractory, chronic spontaneous urticaria (CSU). By blocking circulating IgE …

Omalizumab (a recombinant, humanized anti-immunoglobulin-E anti-body) has been shown
in three pivotal Phase III trials (ASTERIA I, II and GLACIAL) and real-world studies to be …

Chronic spontaneous urticaria (CSU) is a heterogeneous condition that can severely impact
quality of life. Consequently, rapid disease control is essential. First-line treatment of the …

Omalizumab is approved for use in chronic spontaneous urticaria (CSU); however, it is not
approved for chronic inducible urticaria (CIndU). The aim of the present study was to assess …

Background: Previous data have shown the high efficacy of omalizumab in chronic
spontaneous urticaria (CSU). However, factors that may be effective on the response to …

Background: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU).
Studies investigating the use of higher doses of omalizumab in patients unresponsive to …

Biomarkers that are able to predict the response to omalizumab (OMA) in chronic
spontaneous urticaria (CSU) are highly valued. The aim of our study was to evaluate the …

Sažetak Chronic spontaneous urticaria can be treated with several drugs such as
antihistamines, leukotriene antagonists, cyclosporine, doxepin, hydroxychloroquine …